Annual Drug Patent Expirations for KISQALI
Kisqali is a drug marketed by Novartis and is included in two NDAs. It is available from one supplier. There are eight patents protecting this drug.
This drug has one hundred and sixty-five patent family members in fifty-one countries.
The generic ingredient in KISQALI is letrozole; ribociclib succinate. One supplier is listed for this compound. Additional details are available on the letrozole; ribociclib succinate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
